Physical Activity Program for Breast and Colon Cancer Survivors
Trial Summary
What is the purpose of this trial?
The purpose of this research study is to determine whether using the physical activity index screener, exercise coaching, and self-monitoring will increase physical activity and reduce time spent sitting or being inactive in patients who had breast or colon cancer.
Do I need to stop my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications. It seems focused on increasing physical activity rather than changing medication use.
What data supports the effectiveness of the treatment Physical Activity Program for Breast and Colon Cancer Survivors?
Is physical activity safe for cancer survivors?
How is the Physical Activity Program for Breast and Colon Cancer Survivors treatment different from other treatments?
Research Team
Shirley Bluethmann
Principal Investigator
Wake Forest Baptist Comprehensive Cancer Center
Eligibility Criteria
This trial is for breast and colon cancer survivors who are interested in increasing their physical activity. Participants should be willing to use educational materials, wear an activity tracker, complete health surveys, and possibly receive exercise coaching calls.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Pre-exercise Consultation
Participants receive a pre-exercise screening call and consultation
Exercise Intervention
Participants engage in exercise sessions supported by coaching and self-monitoring tools
Follow-up
Participants are monitored for adherence and retention through questionnaires
Treatment Details
Interventions
- Physical Activity Index Assessment (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Wake Forest University Health Sciences
Lead Sponsor
Dr. L. Ebony Boulware
Wake Forest University Health Sciences
Chief Medical Officer since 2022
MD from Duke University School of Medicine, MPH from Johns Hopkins Bloomberg School of Public Health
Dr. Julie Ann Freischlag
Wake Forest University Health Sciences
Chief Executive Officer since 2020
BS from University of Illinois, MD from Rush University
National Cancer Institute (NCI)
Collaborator
Dr. Douglas R. Lowy
National Cancer Institute (NCI)
Chief Executive Officer since 2023
MD from New York University School of Medicine
Dr. Monica Bertagnolli
National Cancer Institute (NCI)
Chief Medical Officer since 2022
MD from Harvard Medical School